Robert Lenz's Insider Trades & SAST Disclosures
Robert Lenz's most recent trade in Neumora Therapeutics Inc. was a trade of 5,614 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on Feb. 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Lenz.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Sale of securities on an exchange or to another person at price $ 1.67 per share. | 18 Feb 2025 | 5,614 | 309,092 | - | 1.7 | 9,383 | Common Stock |
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 502,934 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 502,934 | 502,934 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Sale of securities on an exchange or to another person at price $ 15.09 per share. | 09 Oct 2024 | 8,260 | 314,706 | - | 15.1 | 124,603 | Common Stock |
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 09 Oct 2024 | 5,563 | 322,966 | - | 15.0 | 83,507 | Common Stock |
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Sale of securities on an exchange or to another person at price $ 11.81 per share. | 17 Sep 2024 | 30,788 | 339,205 | - | 11.8 | 363,736 | Common Stock |
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Sale of securities on an exchange or to another person at price $ 12.09 per share. | 17 Sep 2024 | 10,676 | 328,529 | - | 12.1 | 129,091 | Common Stock |
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Sale of securities on an exchange or to another person at price $ 11.43 per share. | 12 Sep 2024 | 32,948 | 369,993 | - | 11.4 | 376,665 | Common Stock |
| Neumora Therapeutics Inc. | Robert Lenz | Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Lenz Robert | Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 50,000 | 402,941 | - | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges